This compound is primarily utilized in the field of medicinal chemistry, particularly in the development of targeted cancer therapies. It functions as a key component in proteolysis-targeting chimeras (PROTACs), which are designed to degrade specific disease-causing proteins within cells. Its structure allows it to bind effectively to E3 ubiquitin ligase, facilitating the tagging and subsequent degradation of target proteins. This mechanism is especially valuable in treating cancers driven by proteins that are traditionally difficult to inhibit with conventional drugs. Additionally, it is explored in research for its potential in treating neurodegenerative diseases by targeting misfolded proteins. Its application extends to the study of protein-protein interactions and cellular pathways, providing insights into disease mechanisms and therapeutic strategies.